Medical Care Technologies (OTC PINK:MDCE) Initiates Preparatory Phase for Self-Conducted Research Studies on AI Mental Health and Preventive Biometrics Modules

Rhea-AI Summary

Medical Care Technologies (OTC PINK:MDCE) announced on October 8, 2025 that it is beginning preparatory, internal non-clinical research on two consumer AI modules: the Mental Health & Micro-Expression Tracker and the Preventive Health & Facial Biometrics Analyzer. The studies will be self-conducted by MDCE's Consumer AI Division to test algorithmic performance, consistency, and data reliability in real-world conditions.

The Tracker uses facial landmarking and emotion-recognition networks to monitor subtle stress and focus shifts; the Biometrics Analyzer uses colorimetric and vascular mapping to evaluate visible wellness indicators. Results are intended for internal model refinement and to support future wellness-research collaborations. The company emphasized accuracy, transparency, and that these tools are for self-monitoring rather than clinical diagnosis.

MESA, ARIZONA / ACCESS Newswire / October 8, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging innovator in AI-powered preventive healthcare, announced that it is preparing to conduct internal, non-clinical research studies on the consumer-facing components of its AI health platform - the Mental Health & Micro-Expression Tracker and the Preventive Health & Facial Biometrics Analyzer.

These studies are part of the company's Consumer AI Division, which focuses on self-monitoring, behavioral research, and preventive awareness rather than clinical diagnosis. Both modules extend MDCE's broader vision of combining facial, ocular, and skin imaging analytics to forecast early health changes through accessible, camera-based AI tools.

Research Overview:

The Mental Health & Micro-Expression Tracker uses advanced facial landmark tracking and emotion-recognition networks to observe subtle shifts in stress, focus, and emotional balance.

The Preventive Health & Facial Biometrics Analyzer applies colorimetric and vascular mapping algorithms to evaluate visible wellness indicators such as tone, elasticity, and fatigue.

Both will undergo self-conducted algorithmic testing to assess performance consistency and data reliability under diverse real-world conditions. Results will be used internally to refine MDCE's AI models and support future wellness-research collaborations.

"Our goal is to ensure that every module - clinical or consumer - meets a measurable standard of accuracy and transparency," said CEO Marshall Perkins III. "These studies demonstrate our commitment to technical rigor and responsible AI development across all health verticals."

Forward-Looking Statements / Safe Harbor

This release includes forward-looking statements regarding future research activities and product development. Actual results may differ due to technical, regulatory, or operational variables. Medical Care Technologies Inc. assumes no obligation to update such statements.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC Pink:MDCE) develops AI-based imaging systems that combine facial, ocular, and dermatological analytics to advance predictive and preventive healthcare. Its modular platform includes both FDA-eligible clinical applications and consumer-focused research tools.

Visit www.medicalcaretechnologies.com for more information.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

FAQ

What studies did MDCE announce on October 8, 2025 for OTC PINK:MDCE?

MDCE announced internal, non-clinical research on a Mental Health & Micro-Expression Tracker and a Preventive Health & Facial Biometrics Analyzer.

How will MDCE test the Mental Health & Micro-Expression Tracker (MDCE)?

MDCE will perform self-conducted algorithmic testing using facial landmark tracking and emotion-recognition networks to assess consistency under diverse real-world conditions.

Will MDCE’s biometric modules be used for clinical diagnosis?

No; MDCE says the modules are for consumer self-monitoring and preventive awareness, not clinical diagnosis.

What does the MDCE announcement mean for shareholders in the near term?

The announcement signals internal R&D activity and model refinement but does not include funding, revenue, or regulatory milestones affecting near-term financials.

How will MDCE use results from the October 2025 consumer AI studies?

Results will be used to refine MDCE's AI models and to support potential future wellness-research collaborations.

Are there regulatory or clinical approvals described in MDCE’s October 8, 2025 release?

No regulatory approvals or clinical trial outcomes were reported; the release notes the work is non-clinical and forward-looking.